| Title | Carvedilol increases ANP plasma levels in hypertensive patients | |
| Author | P.C. Papadopoulos¹, P. Kotridis¹, B. Kokkas², V. Koutsimanis¹, G. Aidonidis¹, G. Dadoush¹, O. Gouli¹, M. Karamouzis³, A. Kouyoumtzis², G. Sakantamis¹, D.I. Hatseras⁴ and C.L. Papadopoulos¹
Departments of 1. Cardiology 2nd, 2. Pharmacology and 3. Biochemistry, Medical School, Aristotle University of Thessaloniki, Greece 4. Department of Cardiology, Medical School, Demokritus University of Thrace, Greece |
|
| Citation | Papadopoulos, P.C., Kotridis, P., Kokkas, B., Koutsimanis, V., Aidonidis, G. et al: Carvedilol increases ANP plasma levels in hypertensive patients, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 283-284 (2006) | |
| Publication Date | Accepted for publication: 19-20 May 2006 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Carvedilol, ANP, hypertension, β-adrenergic blockers. | |
| Other Terms | review article | |
| Summary | Twenty five patients with moderate essential hypertension were studied for 30 days in order to evaluate the medium term effects of carvedilol on atrial natriuretic peptide (ANP) levels. This substance blocks the β1 and β2 adrenenergic receptors as well as α1 adrenergic receptors. In addition, it has strong antioxidative and anti-proliferative properties. The drug was given orally and the dose was 12.5mg twice a day. Quantitative determination of human ANP was made by radioimmunoassay procedure (RIA). At the end of this clinical trial, mean plasma levels of ANP rose during treatment by 21.18% (from 37.60 μg/ml to 45.83 μg/ml) while both systolic (SBP) and diastolic (DBP) blood pressure as well as diameters of the left cardiac cavities were decreased in a statistically significant way. The ratio ANP/SBP was also increased by 46.6% in a statistically significant way. These findings support the suggestion, that the increase in plasma ANP following the administration of β-adrenergic blockers to hypertensive patients is a primary effect of beta blockade and not a mechanical one secondary to a negative inotropic action on the left ventricle and obviously contributes to the antihypertensive action. | |
| References | 1. Papadopoulos C.L., Kokkas B., Kotridis P., et al.: The effect of β1-blocker bisoprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Intern. J. Angiology 4: 165-168 (11995)
2. Papadopoulos C.L., Kokkas B., Kotridis P., et al.: The effect of β1-blocker / β2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Cardiovasc. Drugs Ther. 12: 345-346 (1998) 3. Papadopoulos C.L., Kokkas B., Anogiannakis G.: Beta blockers and atrial natriuretic peptide (ANP) in hypertension. Intern. J. Immunopathol. Pharmacol. 13: 107-110 (2000) 4. Papadopoulos C.L., Kokkas B.A.: Atrial natriuretic peptide contributes to the antihypertensive action of many drugs. Eur. J. Drug Metabol. Pharmacokinet. 28: 55-58 (2003) 5. Bauriedel G., Skowasch D., Hofling B.: Carvedilol as vasodilating -blocker for the treatment of hypertensive patients with peripheral vascular disease – a pilot study. Herz/Kreislauf 32: 69-73 (2000) 6. Hama J., Nagata S., Takenaka T., et al.: Atrial natriuretic peptide and antihypertensive action due to beta – blockade in essential hypertensive patients. Angiology 46: 511-516 (1995) 7. Kokkas B., Kotridis P., Karamouzis M., et al.: Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil. Eur. J. Drug Metab. Pharmacokinet. 27: 45-48 (2002) 8. Iwasaki T., Niwa A., Shinoda T., et al.: Effects of calcium antagonists and nitroglycerin on atrial natriuretic peptide in normal subjects and patients with essential hypertension. Angiology 40: 24-28 (1989) 9. Hollenberg M., Plum J., Heering P., et al.: Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. J. Hypertension 9: 819-824 (1991) 10. Geller D., Currie M., Wakitani K.: Atriopeptides. Biochem. Biophys. Res. Commun. 120: 333-338 (1984) 11. Rosmalen F., Horman J., Tan A., et al.: A sensitive radio- immunoassay of atrial natriuretic peptide in human plasma; some guidelines for clinical applications. Z. Kardiol. 77 (Suppl.2): 20-25 (1998) 12. Karamouzis M., Mandroukas K., Deligiannis D., et al.: Changes in atrial natriuretic peptide (a-ANP) in long distance swimmers. Clin. Chem. Enzym. Comms. 6: 191-195 (1994) 13. Papadopoulos C.L., Kokkas B., Kotridis P., et al.: Plasma atrial natriuretic peptide in essential hypertension after angiotensin coverting enzyme inhibition. Intern. J. Angiology 4: 44-45 (1995) 14. Kotridis P., Kokkas B., Karamouzis M., Sakadamis G., Kanonidis I., Dadous G., Karadona G., Gouli O., Karadoumanis J., Papadopoulos P.C., Papadopoulos C.L.: Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan. Blood Pressure 11: 91-94 (2002) 15. Kotridis P.,Kokkas B., Kyriakou P., Karamouzis M., Salpigidis G., Karantona Ch., Karadoumanis J., Ginis Th., Goulis Ο, Papadopoulos P.C, Vakalopoulos C. , Sakantamis G., Dimitriadou. A., Mirtsou-Fidani V., Papadopoulos C.L.: Plasma Atrial Natriuretic Peptide in Essential Hypertension after Treatment with terazocin. Eur. J. Drug Metabol. Pharmacokinet. 28: 143-146 (2003) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|